Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

NCT07772882 is registered in ClinicalTrials.gov with Rebecca Arend as lead sponsor.

NCT NCT07772882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07772882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Lead sponsor
Rebecca Arend
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
January 31, 2029
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancers, peritoneal carcinoma, platinum resistant ovarian cancer